glutamic acid has been researched along with efaroxan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dreshaj, IA; Ernsberger, P; Haxhiu, MA; Tolentino-Silva, FP; Waldbaum, S | 1 |
| García-Sevilla, JA; Keller, B | 1 |
2 other study(ies) available for glutamic acid and efaroxan
| Article | Year |
|---|---|
alpha(2)-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Amygdala; Animals; Antihypertensive Agents; Benzofurans; Binding, Competitive; Blood Pressure; Brain Chemistry; Glutamic Acid; Heart Rate; Hypertension; Imidazoles; Imidazoline Receptors; Injections, Intravenous; Medulla Oblongata; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Microinjections; Pons; Receptors, Adrenergic, alpha-2; Receptors, Drug | 2000 |
Inhibitory effects of imidazoline receptor ligands on basal and kainic acid-induced neurotoxic signalling in mice.
Topics: Animals; Benzofurans; Cerebral Cortex; Cyclin-Dependent Kinase 5; Glutamic Acid; Hippocampus; Idazoxan; Imidazoles; Imidazoline Receptors; Kainic Acid; Ligands; Male; Mice; Neurodegenerative Diseases; Neuroprotective Agents; Styrenes; Time Factors | 2016 |